IBI310 not checked

Innovent · CTLA-4

FollowEvery change as it happens, and a Monday email
Next date
Phase 2/3 trial completes
Trials
21 active
39 in total · 30 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“1 mg/kg intravenous infusion, administered on Day 1 of each 6-week treatment cycle”In the company’s words, NCT07490262 on ClinicalTrials.gov
Tested for
Hepatocellular Carcinoma (HCC)
Main trialPhase 2/3
“This study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who are: (1) treatment-naive to systemic therapy; and (2) either unsuitable for curative-intent surgical resection or local therapy, or have experienced disease progression following prior surgical resection or local therapy.”In the company’s words, NCT07490262 on ClinicalTrials.gov
Other names
CTLA-4

Other drugs for Hepatocellular Carcinoma (HCC)

All 130 drugs for Hepatocellular Carcinoma (HCC)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials39

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 31 Dec 2027 A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Phase 3Completed 31 Dec 2025 A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Phase 2Terminated 26 Oct 2020 IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
Phase 2Completed 20 Nov 2023 A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
Phase 1/2Unknown 31 Dec 2023 IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
Phase 1Completed 10 Sep 2021 A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
Phase 1Completed 25 Apr 2022 IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
Phase 1Completed 2 May 2022 A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab(YERVOY)in Adult Healthy Chinese Male Volunteers
Phase 1Completed 31 Jul 2022 IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
Phase 3Authorised not given First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)
Phase 1/2Ended not given A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladder sparing curative treatment for muscle invasive bladder cancer: the CRIMI study
Phase 1/2Authorised not given A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (Indi-Blade)
Phase 2Ended not given Breaking the big Five Barriers of Brain Metastasis: A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain CA209-7WF / Break B5-BM-NSCLC
Phase 2Ended not given Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer
Phase 2Authorised not given Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial
Phase 3Authorised not given Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA
Phase 2Ended not given Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC) patients with synchronous Brain metastases_NIVIPI-Brain
Phase 3Ended not given RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype
Phase 2Ended not given Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer (SOGUG-VEXILLUM)
Phase 3Ended not given IFCT-1701 DICIPLE A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Phase 2Authorised not given Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for recurrence or distant metastases (NESCIO-trial; M21NSC; CA209-6DJ)
Phase 1/2Authorised not given (CHOPI) Phase 1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal Melanoma.
Phase 2Authorised not given Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing extensive curative surgery and radiotherapy: Matisse-2
Phase 2Authorised not given Uptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanoma
Phase 2Ended not given Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial
Phase 2Authorised not given Immune-Related Rheumatological and neurological Adverse Events study (IRRAE study)
Phase 2Authorised not given Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma: phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab and ipilimumab - ADJORL1
Phase 3Authorised not given Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
Phase 1/2Authorised not given A randomized phase II clinical trial on intratumoral AS01B/ipilimumab plus intravenous nivolumab with or without autologous CD1c(BDCA-1)+ / CD141(BDCA-3)+ myeloid dendritic cells.
Phase 1Authorised not given A phase IB clinical trial on neoadjuvant and intraoperative intracranial administration of triple immune checkpoint blockade plus myeloid dendritic cells in patients with recurrent high-grade glioma
Phase 2Authorised not given Analysis of the efficacy and safety of two combination treatment regimens of nivolumab and ipilimumab in patients with dMMR and / or MSI metastatic colorectal cancer: A GERCOR open-label, randomized, non-comparative, two-stage phase II trial (NIPISAFE)
Phase 1/2Ended not given LAPTOP: PHASE 1/2 STUDY IN BORDELINE RESECTABLE, LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER TO ASSESS SAFETY AND POTENTIAL EFFICACY OF DUAL CHECKPOINT INHIBITION IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL FOLLOWED BY IMMUNE-CHEMORADIATION.
Phase 2Authorised not given A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases
Phase 4Authorised not given Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE)
Phase 2Authorised not given A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1
Phase 2Ended not given A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
Phase 3Authorised not given SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma
Phase 2Authorised not given A Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer
Phase 2/3Authorised not given DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IBI310

Following is part of Solo: you see every change to IBI310 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in